Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
ROPIVACAINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP38–NF33 | 5225 | 25-Sep-2015 | 1-Oct-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 2 of USP Ropivacaine Related Compound B RS: Change (R)-ropivacaine hydrochloride monohydrate; (R)-(−)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate. to: (R)-Ropivacaine hydrochloride monohydrate; (R)-(+)-1-… Read More |
BROMPHENIRAMINE MALEATE | SPECIFIC TESTS/Optical Rotation, Specific Rotation <781> | USP38–NF33 | 2475 | 25-Sep-2015 | 1-Oct-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 1: Delete Specific Rotation AND Line 1 of Sample: Change 100 mg/mL in water to: 100 mg/mL in water at 20° |
IPRATROPIUM BROMIDE | DEFINITION | USP38–NF33 | 3932 | 25-Sep-2015 | 1-Oct-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 2: Change (C20H30BrNO3 · H2O) to: (C20H30BrNO3) |
OXAZEPAM | SPECIFIC TESTS/pH <791> | USP38–NF33 | 4683 | 25-Sep-2015 | 1-Oct-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 1: Change Sample solution: 20 mg/mL to: Sample: A suspension of 1 g of Oxazepam in 50 mL water |
RIVASTIGMINE TARTRATE | IMPURITIES/Organic Impurities/Procedure 1 | USP38–NF33 | 5213 | 25-Sep-2015 | 1-Oct-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Footnote c of Impurity Table 1: Change (S)-3-[1-(Dimethylamino)ethyl]phenyl dimethylcarbamate (rivastigmine related compound B). to: (S)‐3‐[1‐(Dimethylamino)ethyl]phenyl dimethylcarbamate (racemic mixture is rivastigmine related compound B). |
SODIUM STEARYL FUMARATE | SPECIFIC TESTS/Fats and Oils, Saponification Value <401> | USP38–NF33 | 6877 | 25-Sep-2015 | 1-Oct-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 6 of Analysis: Change Rinse the condenser with two 10-mL portions of 70% alcohol, add phenolphthalein TS, to: Rinse the condenser with 10 mL of 70% alcohol, followed by three 10-mL portions of water, collecting the rinsings in the flask. Cool, rinse the sides of the flask… Read More |
<81> ANTIBIOTICS—MICROBIAL ASSAYS | APPENDIX 1. FORMULAS FOR MANUAL CALCULATIONS OF REGRESSION AND SAMPLE CONCENTRATION | USP38–NF33 | 133 | 25-Sep-2015 | 1-Oct-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 19: Change b = [(4 × 17.222) + (2 × 16.511) − (2 × 14.989) − (4 × 14.020)]/{5[ln(7.81)] − ln(3.2)} = 3.551 to: b = [(4 × 17.222) + (2 × 16.511) − (2 × 14.989) − (4 × 14.020)]/{5[ln(7.81) − ln(3.2)]} = 3.551 |
ETHOTOIN | Related compounds/Procedure | USP38–NF33 | 3415 | 25-Sep-2015 | 1-Oct-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 11:Change weight, in mg, on the anhydrous basis, of the portion of Ethotoin taken; to: weight, in mg, of the portion of Ethotoin taken; |
NALOXONE HYDROCHLORIDE | IMPURITIES/Noroxymorphone Hydrochloride [(−)-4,5α-Epoxy-3,14-Dihydroxymorphinan-6-one-hydrochloride] and Other Impurities/Chromatographic system | USP38–NF33 | 4486 | 25-Sep-2015 | 1-Oct-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Add Application volume: 5 µL |
METHOTREXATE | IMPURITIES/Organic Impurities/Procedure 1: Related Compounds | USP38–NF33 | 4318 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 15 of Analysis: Change methotrexate related compound E free acid to: methotrexate related compound E free base AND Line 8 of the second variable definition list for Analysis: Change methotrexate related compound E free acid to: methotrexate related… Read More |
TETRACAINE HYDROCHLORIDE FOR INJECTION | Chromatographic purity | USP38–NF33 | 5508 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 1: Change Dissolve an accurately weighed quantity of Tetracaine Hydrochloride for Injection in water to obtain a test solution containing 50 mg per mL, and proceed as directed in the test for Chromatographic purity under Tetracaine, beginning with “Prepare a Standard… Read More |
METHACRYLIC ACID AND METHYL METHACRYLATE COPOLYMER | ASSAY/Procedure | USP38–NF33 | 6755 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 3 of Acceptance criteria: Delete on the dried basis AND Line 5 of Acceptance criteria: Delete on the dried basis |
<1056> BIOTECHNOLOGY-DERIVED ARTICLES -- POLYACRYLAMIDE GEL ELECTROPHORESIS | INTRODUCTION | Harmonization (Official December 01, 2015) | Online | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | A paragraph before the Introduction was deleted: This chapter provides guidance and procedures used for characterization of biotechnology-derived articles by polyacrylamide gel electrophoresis. Portions of the chapter that are not harmonized with the other two pharmacopeias are marked by… Read More |
AMOXICILLIN TABLETS FOR ORAL SUSPENSION | ASSAY/Procedure | USP38–NF33 | 2225 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 6 of Analysis: Change Result = (rU/rS) × (CS/CU) × P × (1/F) ×100 to: Result = (rU/rS) × (CS/CU) × P × F… Read More |
TETRACAINE HYDROCHLORIDE INJECTION | Identification | USP38–NF33 | 5507 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 1 of A: Change It responds to Identification test B under Tetracaine Hydrochloride. to: Dissolve 100 mg in 10 mL of water, and add 1 mL of potassium thiocyanate solution (1 in 4): a crystalline precipitate is formed. Recrystallize the precipitate from… Read More |
METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER | ASSAY/Procedure | USP38–NF33 | 6753 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 1 of Acceptance criteria: Delete on the dried basis |
DOXAZOSIN MESYLATE | IMPURITIES/Organic Impurities/Analysis | First Supplement to USP38–NF33 | 7387 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 3 of the variable definition list: Change rS = peak response of each impurity from the Standard solution to: rS= peak response of each impurity or doxazosin mesylate (for calculating unspecified impurities) from the Standard solution… Read More |
METOLAZONE TABLETS | ASSAY/Procedure | USP38–NF33 | 4368 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Change the subsection Standard solution: 5 µg/mL of USP Metolazone RS in methanol to: Standard stock solution: 0.25 mg/mL of USP Metolazone RS in methanol Standard solution: 5 µg/mL of USP Metolazone RS in Mobile phase from Standard stock solution … Read More |
TETRACAINE HYDROCHLORIDE IN DEXTROSE INJECTION | Identification | USP38–NF33 | 5509 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 1 of B: Change It responds to Identification test C under Tetracaine Hydrochloride. to: A solution of 100 mg in 5 mL of water meets the requirements of the tests for Chloride <191>. |
PURIFIED STEARIC ACID | ASSAY/Procedure/System suitability/Suitability requirements | USP38–NF33 | 6919 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 2 of Relative standard deviation: Change six replicate injections of Sample solution; to: six replicate injections; |
ESTRADIOL AND NORETHINDRONE ACETATE TABLETS | IMPURITIES/Organic Impurities/Procedure/System suitability | USP38–NF33 | 3385 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 2 of the Note: Change 1.0, 1.4, and 3.0, to: 1.0, 1.1, and 1.7, |
TETRACAINE HYDROCHLORIDE FOR INJECTION | Identification | USP38–NF33 | 5508 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 1 of B: Change It responds to Identification test B under Tetracaine Hydrochloride. to: Dissolve 100 mg in 10 mL of water, and add 1 mL of potassium thiocyanate solution (1 in 4): a crystalline precipitate is formed. Recrystallize the precipitate from… Read More |
METHACRYLIC ACID AND METHYL METHACRYLATE COPOLYMER | DEFINITION | USP38–NF33 | 6755 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Methacrylic acid units in Methacrylic Acid and Methyl Methacrylate Copolymer are NLT 27.6% and NMT 50.6%, calculated on the dried basis. to: Methacrylic acid units in Methacrylic Acid and Methyl Methacrylate Copolymer, previously dried, are NLT 27.6% and NMT 50.6%. |
STEARIC ACID | ASSAY/Procedure/System suitability/Suitability requirements | Harmonization (Official May 01, 2015) | Online | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 3 of Relative standard deviation: Change peaks (from six replicate injections of Sample solution); to: peaks, from six replicate injections; |
OXAPROZIN TABLETS | IMPURITIES/Organic Impurities/System suitability/Suitability requirements | USP38–NF33 | 4681 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Delete the subsection Signal-to-noise ratio: NLT 3000 |
METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER | DEFINITION | USP38–NF33 | 6753 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 4: Change Methacrylic acid units in Methacrylic Acid and Ethyl Acrylate Copolymer are NLT 46.0% and NMT 50.6%, calculated on the dried basis. to: Methacrylic acid units in Methacrylic Acid and Ethyl Acrylate Copolymer, previously dried, are NLT 46.0% and NMT 50.6%. |
ALMOTRIPTAN MALATE | IMPURITIES/Limit of Almotriptan Related Compound D and Almotriptan N-Dimer | First Supplement to USP38–NF33 | 7325 | 31-Jul-2015 | 1-Aug-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 1of Internal standard solution: Change 4-hydroxy-phenylpiperidine to: 4-hydroxy-4-phenylpiperidine |
REAGENTS | REAGENT SPECIFICATIONS/Ferric Sulfate | USP38–NF33 | 1841 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 1: Change [10028-22-5] to: [15244-10-7] |
CEFIXIME | CHEMICAL INFORMATION | USP38–NF33 | 2665 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 9: Change [79350-37-1]. to: [125110-14-7]. Anhydrous [79350-37-1]. |
IDARUBICIN HYDROCHLORIDE INJECTION | SPECIFIC TESTS/Constituted Solution | USP38–NF33 | 3834 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Delete the Constituted Solution test. |
METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP38–NF33 | 4348 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 3 of USP Methylphenidate Related Compound A RS: Change 255.75 to: 255.74 |
SODIUM CETOSTEARYL SULFATE | IMPURITIES/Limit of Free Cetostearyl Alcohol | USP38–NF33 | 6868 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 5 of Analysis: Change Result = 100(rA + rB) × WIS × (SA(corr) × W) to: Result = 100(rA + rB) × WIS/(SA(corr) × W) … Read More |
TELMISARTAN TABLETS | IDENTIFICATION/A. Ultraviolet Absorption <197U> | Revision Bulletin (Official December 01, 2014) | Online | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 3: Change as obtained in the test for Dissolution. to: as obtained in the test for Dissolution, Test 1. |
<1197> GOOD DISTRIBUTION PRACTICES FOR BULK PHARMACEUTICAL EXCIPIENTS | SECTION 2: QUALITY, ORGANIZATION, AND DOCUMENTATION/2.8 Contract Activities | USP38–NF33 | 1396 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Footnote 2: Change http://whqlibdoc.who.int/trs/WHO_TRS_917_annex2.pdf (Accessed June 30, 2011) to: … Read More |
BENZOYL PEROXIDE GEL | IMPURITIES/Organic Impurities | USP38–NF33 | 2399 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 18 of Standard solution D: Change hydrous benzoyl peroxide (C14H10O4). to: anhydrous benzoyl peroxide (C14H10O4). |
CUPRIC SULFATE | ASSAY/Procedure/Titrimetric system | USP38–NF33 | 2965 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 1 of Endpoint detection: Change Potentiometric to: Visual |
METHYLPHENIDATE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP38–NF33 | 4345 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 3 of USP Methylphenidate Related Compound A RS: Change 255.75 to: 255.74 |
ORAL REHYDRATION SALTS | ASSAY/Dextrose | USP38–NF33 | 5145 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 10 of Analysis: Change A = 100 mm divided by the length of the polarimeter tube (mm) to: A = 100 divided by the length of the polarimeter tube (dm) AND Line 21 of Analysis: Change A = 100 mm divided by the length of the polarimeter tube (mm… Read More |
SODIUM CHLORIDE | IMPURITIES/Limit of Phosphates | Harmonization (Official December 01, 2015) | Online | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 2 of Analysis: Change add 4 mL of sulfomolybdic acid TS, to: add 4 mL of Sulfomolybdic acid solution, |
<1047> GENE THERAPY PRODUCTS | REGULATIONS AND STANDARDS | USP38–NF33 | 883 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 8: Delete and, in particular, www.fda.gov/cber/publications.htm |
CROMOLYN SODIUM OPHTHALMIC SOLUTION | Assay | USP38–NF33 | 2962 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 1 of Procedure: Change Proceed as directed for Procedure in the Assay under Cromolyn Sodium Inhalation Solution. to: Concomitantly determine the absorbances of the Standard preparation and the Assay preparation in 1-cm cells at the… Read More |
ALUMINUM CHLOROHYDRATE | CHEMICAL INFORMATION | USP38–NF33 | 2130 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 8: Change Dihydrate [12042-91-0].Anhydrous [1327-41-9]. to: Dihydrate [12359-72-7].Anhydrous [12042-91-0]. |
CEFOTAXIME FOR INJECTION | ASSAY/Procedure | USP38–NF33 | 2678 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 10 of the Calculate statement in the Analysis: Change CU = nominal concentration of cefotaxime sodium in Sample solution 1, 2, 3, or 4 (mg/mL) to: CU = nominal concentration of cefotaxime in Sample solution 1… Read More |
LEVETIRACETAM | IMPURITIES/Organic Impurities | USP38–NF33 | 4060 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 2 of Procedure 2: Change Buffer, Solution A, Solution B, Mobile phase, System suitability solution, and Chromatographic system: to: Buffer, Solution A, Solution B, Mobile phase, System suitability solution, Chromatographic system, and System suitability… Read More |
PROTAMINE SULFATE | SPECIFIC TESTS/pH <791> | USP38–NF33 | 5069 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Delete the test for pH |
NIACIN | IMPURITIES/Related Compounds | First Supplement to USP38–NF33 | 7447 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Row 14 of Column 1 of Table 2: Change Total impurities to: Total specified impurities |
<232> ELEMENTAL IMPURITIES--LIMITS | DRUG SUBSTANCE AND EXCIPIENTS/Table 2 | Second Supplement to USP38–NF33 | 7594 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 1 of Row 1 of Column 2: Change (g/g) to: (µg/g) AND Line 1 of Row 1 of Column 3: Change (g/g) to: (µg/g) AND Line 1 of Row 1 of Column 4: Change (g/g) to: (µg/g) |
<1197> GOOD DISTRIBUTION PRACTICES FOR BULK PHARMACEUTICAL EXCIPIENTS | SECTION 4: RETURNED GOODS, DISPATCH, TRANSPORT, IMPORTATION, ADULTERATION, AND TRACEABILITY/4.7 Importation | USP38–NF33 | 1396 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Footnote 11: Delete http://www.fda.gov/ForIndustry/ImportProgram/AdmissibilityDeterminationsforShipmentsofForeign-originOASIS/ucm077691.htm (Accessed June 6,… Read More |
CEFAZOLIN FOR INJECTION | ASSAY/Procedure | USP38–NF33 | 2652 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 7 of Analysis: Change Result = (RU/RS) × (CS/CU) × P × F × 100 to: Result = (RU/RS) × (CS… Read More |
FEXOFENADINE HYDROCHLORIDE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 1 | USP38–NF33 | 3487 | 29-May-2015 | 1-Jun-2015 | USP39–NF34 | USP39–NF34 | Line 4 of System suitability solution: Change [Note—A small amount of acetic acid, to: [Note—A small amount of glacial acetic acid, |